• 1. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490
• 2. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 5. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Introduction to 3-BROMO-5-CHLOROBENZAMIDE (CAS No. 933671-77-3)

3-BROMO-5-CHLOROBENZAMIDE, identified by the Chemical Abstracts Service Number (CAS No.) 933671-77-3, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This benzamide derivative, characterized by the presence of both bromo and chloro substituents at specific positions on the benzene ring, exhibits unique chemical properties that make it a valuable intermediate in the synthesis of various bioactive molecules.

The structural motif of 3-BROMO-5-CHLOROBENZAMIDE positions it as a versatile building block for the development of novel therapeutic agents. The electron-withdrawing nature of the chloro and bromo groups enhances its reactivity, facilitating further functionalization through nucleophilic aromatic substitution, cross-coupling reactions, or other synthetic transformations. Such modifications are crucial in designing molecules with tailored pharmacological profiles, including enhanced binding affinity to biological targets or improved metabolic stability.

In recent years, the pharmaceutical industry has placed increasing emphasis on the discovery and development of small-molecule inhibitors targeting complex biological pathways. 3-BROMO-5-CHLOROBENZAMIDE has emerged as a key intermediate in this endeavor, particularly in the synthesis of kinase inhibitors and other enzyme-targeted drugs. Its ability to serve as a precursor for more complex structures underscores its importance in modern drug design strategies.

One of the most compelling aspects of 3-BROMO-5-CHLOROBENZAMIDE is its role in the development of targeted therapies for oncological applications. Kinase inhibitors, a class of drugs that modulate the activity of enzymes involved in cancer cell proliferation, often require precise structural motifs to achieve high selectivity and efficacy. The bromo and chloro substituents in 3-BROMO-5-CHLOROBENZAMIDE provide critical handles for further derivatization, enabling medicinal chemists to fine-tune molecular interactions with biological targets such as tyrosine kinases or serine/threonine kinases.

Recent advancements in computational chemistry and structure-based drug design have further highlighted the utility of 3-BROMO-5-CHLOROBENZAMIDE as a scaffold for lead optimization. High-throughput screening (HTS) campaigns and virtual screening methods have been employed to identify novel derivatives with improved pharmacokinetic properties or enhanced target engagement. The compound's structural features allow for rapid diversification of the chemical space, facilitating the identification of compounds with optimized therapeutic profiles.

The synthesis of 3-BROMO-5-CHLOROBENZAMIDE itself is a testament to modern synthetic methodologies. Traditional approaches often involve multi-step sequences involving halogenation and condensation reactions. However, recent innovations have enabled more efficient synthetic routes, including transition-metal-catalyzed cross-coupling reactions that streamline the introduction of bromo and chloro substituents onto the benzene ring. These advancements not only improve yield but also reduce waste, aligning with green chemistry principles.

In addition to its applications in oncology, 3-BROMO-5-CHLOROBENZAMIDE has shown promise in other therapeutic areas, including anti-inflammatory and antiviral drug discovery. Its benzamide core is a well-established pharmacophore found in numerous approved drugs, while the halogenated substituents provide additional opportunities for structure-activity relationship (SAR) studies. By systematically modifying these functional groups, researchers can explore new chemical entities with potential therapeutic benefits.

The growing interest in 3-BROMO-5-CHLOROBENZAMIDE is also driven by its role as a key intermediate in peptidomimetic synthesis. Peptidomimetics are designed to mimic the bioactivity of natural peptides while offering improved pharmacological properties such as oral bioavailability or longer half-life. The benzamide moiety serves as a hinge region that allows for precise spatial arrangement of additional functional groups, enabling high-affinity binding to biological targets without triggering off-target effects.

From a regulatory perspective, 3-BROMO-5-CHLOROBENZAMIDE must be handled and stored under appropriate conditions to ensure stability and purity. While it does not fall under any hazardous material classifications, adherence to good manufacturing practices (GMP) is essential when scaling up production for pharmaceutical applications. Quality control measures must be rigorously applied to monitor impurities and ensure batch-to-batch consistency.

The future prospects for 3-BROMO-5-CHLOROBENZAMIDE are promising, with ongoing research exploring its potential in emerging therapeutic modalities such as gene therapy and RNA interference. The compound's structural flexibility makes it an attractive candidate for developing prodrugs or delivery systems that enhance therapeutic efficacy while minimizing side effects.

In conclusion,3-BROMO-5-CHLOROBENZAMIDE (CAS No. 933671-77-3) represents a critical component in contemporary drug discovery efforts. Its unique structural features and reactivity profile enable its use as a versatile intermediate for synthesizing novel bioactive molecules across multiple therapeutic domains. As research continues to uncover new applications for this compound, its significance in pharmaceutical chemistry is likely to grow further.

• 877149-13-8(Benzamide,4-bromo-2-chloro-6-methyl-)
• 917388-35-3((3-Bromo-5-chlorophenyl)methanamine)
• 791137-22-9(3-Bromo-4-chlorobenzamide)
• 188774-55-2(5-Bromo-2-chlorobenzamide)
• 1228826-41-2(4-Bromo-3-chlorobenzamide)
• 22726-00-7(m-Bromobenzamide)
• 619-56-7(4-Chlorobenzamide)
• 618-48-4(3-Chlorobenzamide)
• 1219794-65-6(4-Chlorobenzamide-2,3,5,6-d4)
• 426265-73-8(4-Bromo-2-chlorobenzamide)